CBAY - CymaBay Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-10,000--
Cost of Revenue43,74712,0049,74811,697
Gross Profit-43,747-2,004-9,748-11,697
Operating Expenses
Research Development14,3776,9346,1935,329
Selling General and Administrative14,38112,3879,6458,871
Non Recurring----
Total Operating Expenses72,50531,32525,58625,897
Operating Income or Loss-72,505-21,325-25,586-25,897
Income from Continuing Operations
Total Other Income/Expenses Net-43-8,832-1,08510,368
Earnings Before Interest and Taxes-72,505-21,325-25,586-25,897
Interest Expense-336-1,080-1,337-913
Income Before Tax-72,548-27,557-26,671-15,529
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-72,548-27,557-26,671-15,529
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-72,548-27,557-26,671-15,529
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-72,548-27,557-26,671-15,529